Myriad's Impact on Gene Patents

Aboy, Mateo; Liddell, Kathleen; Liddicoat, John; Crespo, Cristina

Myriad's Impact on Gene Patents

Nature Biotechnology, Vol. 34, No. 11, p. 1119-1123, Nov. 2016

University of Cambridge Faculty of Law Research Paper No. 58/2017

8 Pages Posted: 4 Aug 2017 Last revised: 25 Jun 2019

See all articles by Mateo Aboy

Kathleen Liddell

University of Cambridge - Faculty of Law

John Liddicoat

University of Cambridge - Faculty of Law; University of Tasmania

Cristina Crespo

University of Cambridge

Date Written: November 8, 2016

Abstract

In the three years since the US Supreme Court’s decision in AMP v Myriad, there has been much debate and speculation about the impact of the Myriad case on the biotech industry, particularly on the status of gene patents. Was it a significant decision or, as Lord Tennyson might have argued, just another decision in a myriad of single instances that make up a confused and confusing law of patents?

Keywords: Patents, BRCA, Myriad, Gene Patents, Patent Publications, Empirical Analysis

JEL Classification: O3, O30, O31, O32, O33, O34

Suggested Citation: Suggested Citation

Aboy, Mateo and Liddell, Kathleen and Liddicoat, Johnathon and Crespo, Cristina, Myriad's Impact on Gene Patents (November 8, 2016). Nature Biotechnology, Vol. 34, No. 11, p. 1119-1123, Nov. 2016, University of Cambridge Faculty of Law Research Paper No. 58/2017, Available at SSRN: https://ssrn.com/abstract=2877645